Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with an autocrine response to GM-CSF

Leukemia

Volumn 10, Issue 9, 1996, Pages 1534-1543

  Estrov, Z ^a,b   Talpaz, M ^a   Ku, S ^a   Harris, D ^a   LaPushin, R ^a   Koller, C A ^a   Hirsh Ginsberg, C ^a   Huh, Y ^a   Yee, G ^a   Kurzrock, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic; Cell line; Granulocyte macrophage colony stimulating factor; Leukemia; Philadelphia chromosome

Indexed keywords

ANTIBODY; BCR ABL PROTEIN; COMPLEMENTARY DNA; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; B LYMPHOCYTE; CANCER GENETICS; CASE REPORT; CELL ULTRASTRUCTURE; CHROMOSOME 22Q; CHROMOSOME 8Q; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; COLONY FORMATION; ENZYME ASSAY; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; LEUKEMIA CELL LINE; LYMPHOCYTE PROLIFERATION; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR BINDING; SOUTHERN BLOTTING;

EID: 9544248645     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Grigg AP. Approaches to the treatment of Philadelphia-positive acute lymphocytic leukemia. Bone Marrow Transplant 1993; 12: 431-435.
2. Annini L, Ferrari A, Cedrone M, Giona F, Lo Coco F, Meloni G, Arcese W, Mandeli F. Adult Philadelphia-chromosome-positive acute lymphoblastic leukemia: experience of treatments during a ten-year period. Leukemia 1994; 8: 664-667.
3. Roberts WM, Rivera GK, Raimondi SC, Santana VM, Sandlund JT, Crist WM, Pui C-H. Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Lancet 1994; 343: 331-332.
4. Rodenhuis S, Smets LA, Slater RM, Behrendt H, Veerman AJP. Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia. New Engl J Med 1985; 313: 51-52.
5. 1) acute lymphocytic leukemia. Proc Natl Acad Sci USA 1986; 83: 1807-1811.
6. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Phildelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosme 22. Cell 1984; 36: 93-99.
7. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. New Engl J Med 1988; 319:990-998.
8. Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo JM, Huh Y, Stass S, Kurzrock R. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood 1991; 78: 2411-2418.
9. Kurzrock R, Shtalrid M, Romero P, Kloetzer WS, Talpaz M, Trujillo IM, Blick M, Beran M, Gutterman JU. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukemia. Nature (Lond) 1987; 324: 631-635.
10. Clark SS, McLaughlin J, Crust WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph-positive CML from Ph-positive ALL. Science 1987; 235: 85-88
11. Chan LC, Karhi KK, Rayter SI, Heisterkamp N, Eridani S, Powles R, Lawler SD, Groffen J, Foulkes JG, Greaves MF, Weidemann LM. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature (Lond) 1987; 325: 635-637.
12. BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res 1993; 53: 3289-3293.
13. Tsuchiya H, Adachi N, Asou N, Takatsuki K, Matsuda I, Kawano F, Murakami T, Mizutani S, Watanabe M. Responses to granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage CSF in Philadelphia-positive acute lymphoblastic leukemia with myeloid surface markers. Blood 1991; 77: 411-413.
14. 1-positive cell lines (Z-119 and Z-181). J Cell Physiol 1996; 166: 618-630.
15. Stass S, Mirro J, Melvin S, Pui C-H, Murphy SB, Williams D. Lineage switch in acute leukemia. Blood 1984; 64: 701-706.
16. Mirro J, Zipf TF, Pui C-H, Kitchingman G, Williams D, Melvin S, Murphy SB, Stass S. Acute mixed-lineage leukemia: clinicopathologic correlations and prognostic significance. Blood 1985; 66: 1115-1123.
17. Neame PB, Soamboonsrup P, Browman G, Barr RD, Saeed N, Chan B, Pai M, Benger A, Wilson WE, Walker IR, McBride JA. Simultaneous or sequential expression of lymphoid and myeloid phenotypes in acute leukemia. Blood 1985; 65: 142-148.
18. Hayashi Y, Kobayaski Y, Hirai H, Hanada R, Yamamoto K, Abe T, Sugita K, Nakazawa S, Suetake N, Hoshino H, Kuroume T, Bessho F, Hayakawa H, Takaku F. Immunoglobulin heavy chain gene rearrangements and mixed lineage characteristics in acute leukemias with the 11;19 translocation. Cancer 1988; 61: 712-720.
19. Buchner T, Hiddemann W, Koenigsmann M, Zuhlsdorf M, Wormann B, Boeckmann A, Freire EA, Innig G, Maschmeyer G, Ludwig W-D, Sauerland M-C, Heinecke A, Schulz G. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or at relapse. Blood 1991; 78: 1190-1197.
20. Kantarjian HM, Estey EH, O'Brien S, Anaissie E, Beran M, Rios MB, Keating MJ, Gutterman J. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinsoide followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 1992; 79: 876-881.
21. Estey EH. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 1994; 83: 2015-2019.
22. Carlo-Stella C, Mangoni L, Almici C, Cotafavi L, Meloni C, Mandelli F, Rissoli V. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. Blood 1992; 80: 2412-2418.
23. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposal for the classification of the acute leukemias. Br J Haematol 1976; 33: 451-458.
24. Graham RC, Karnovsky MJ. The early stages of absorption of injected horseradish peroxidase in proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique. J Histochem Cytochem 1966; 14: 291-302.
25. LeMaistre A, Childs C, Hirsh-Ginsberg C, Reuben J, Cork A, Trujillo J, Anderson B, McCredie K, Freireich E, Stass S. Heterogeneity in acute undifferentiated leukemia. Hematol Pathol 1988; 2: 79-90.
26. Griffin JD. The use of monoclonal antibodies in the characterization of myeloid leukemias. Hematol Pathol 1987; 1: 81-91.
27. Seabright M. A rapid banding technique for human chromosomes. Lancet 1971; 2: 971.
28. Bergsma D, Lindsten JE, Klinger HP, Hamerton JL (eds). An international system for human cytogenetic nomenclature: report of the Standing Committee on Human Cytogenetic Nomenclature. Cytogenet Cell Genet 1978; 21: 309-402.
29. Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman JU, Arlinghaus R. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 1985; 140: 230-238.
30. bcr-abl in chronic myelogenous leukemia. Blood 1987; 70: 233-236.
31. Kurzrock R, Blick MB, Talpaz M, Velasquez WS, Trujillo JM, Kouttab NM, Kloetzer WS, Arlinghaus RB, Gutterman JU. Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia. An Intern Med 1986; 105: 673-679.
32. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 1975; 98: 503-517.
33. Feinberg AD, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1984; 137: 226-267 (Addendum).
34. Thomas PS. Hybridization of denaturated RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA 1980; 77: 5201-5205.
35. Hearing JC, Nicolas J-C, Levine AJ. Identification of Epstein-Barr virus sequences that encode a nuclear antigen expressed in latently infected lymphocytes. Proc Natl Acad Sci USA 1984; 81: 4373-4377.
36. Sambrook J, Frisch EF, Maniatis T. Molecular cloning. A laboratory manual, edn 2. In: Ford N, Nolan C, Ferguson M (eds). In Vitro Amplification of DNA by the Polymerase Chain Reaction. Cold Spring Harbor Press: New York, 1989, pp 14.1-14.35.
37. Dhingra K, Talpaz M, Riggs MG, Eastman PS, Zipf T, Ku S, Kurzrock R. Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias. Blood 1991; 77: 238-242.
38. Arnold LJ Jr, Hammond PW, Wiese WA, Nelson NC. Assay formats involving acridinium-ester-labeled DNA probes. Clin Chem 1989; 35: 1588-1594.
39. Estrov Z, Kurzrock R, Wetzler M, Kantarjian H, Blake M, Harris D, Gutterman JU, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by IL-1 receptor antagonist and souble IL-1 receptors: a novel application for inhibitors of IL-1 activity. Blood 1991; 78: 1476-1484.
40. Estrov Z, Cohen A, Gelfand EW, Freedman MH. Synergistic antioliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Am J Pediatr Hematol Oncol 1988; 10: 288-291.
41. Estrov Z, Kurzrock R, Estey E, Wetzler M, Ferrajoli A, Harris D, Blake M, Guttermann JU, Talpaz M. Inhibition of acute myelogenous leukemia blast proliferation by IL-1 receptor antagonist and soluble IL-1 receptors. Blood 1992; 79: 1938-1945.
42. Ferrajoli A, Zipf TF, Talpaz M, Felix EA, Estrov Z. Growth factors controlling interleukin-4 action on hematopoietic progenitors. Ann Hematol 1993; 67: 277-284.
43. Wognum AW, van Gils FCJM, Wagemaker G. Flow cytometric detection of receptors for interleukin-6 on bone marrow and peripheral blood cells of human and rhesus monkeys. Blood 1993; 81: 2036-2043.
44. Estrov Z, Black RA, Sleath PR, Harris D, Van Q, LaPushin R, Estey EH, Talpaz M. Effect of interleukin-1β converting enzyme (ICE) inhibitor on acute myelogenous leukemia progenitor proliferation. Blood 1995; 86: 4594-4602.
45. Gretch DR, Suter M, Stinski MF. The use of biotinylated monoclonal antibody and stereptavidin affinity chromatography to isolate herpesvirus hydrophobic proteins or glycoproteins. Anal Biochem 1987; 163: 270-277.
46. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph-positive CML from Ph-positive ALL. Science 1987; 235: 85-87.
47. Cohen A, Grunberger T, Vanek W, Dube ID, Doherty PJ, Letarte M, Roifman C, Freedman MH. Constitutive expression and role in growth regulation of interleukin-1 and multiple cytokine receptors in a biphenotypic leukemia cell line. Blood 1991; 78: 94-102.
48. Freedman MH, Grunberger T, Correa P, Axelrad AA, Dube ID, Cohen A. Autocrine and paracrine growth control by granulocyte-monocyte colony-stimulating factor of acute lymphoblastic leukemia cells. Blood 1993; 81: 3068-3075.
49. Estrov Z, Freedman MH. Growth requirements for human actue lymphoblastic leukemia cells: refinement of a clonogenic assay. Cancer Res 1988; 48: 5901-5907.
50. Drach D, Estrov Z, Zhao S, Drach J, Cork A, Collins D, Kantarjian H, Andreeff M. G-CSF, GM-CSF, SCF, PIXY 321, IL-3, and IL-7: receptor binding and effects on clonogenic growth in acute lymphoblastic leukemia. Leuk Lymphoma 1994; 16: 79-88.
51. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985; 313: 745-746.
52. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. New Engl J Med 1980; 303: 878-880.
53. Sporn MB, Roberts AB. Autocrine, paracrine and endocrine mechanisms of growth control. Cancer Surv 1985; 4: 627-632.
54. Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus (EBV)-infected B-cell lines. J Exp Med 1993; 177: 763-774.
55. Malejczyk J, Malejczyk M, Kock A, Urbanski A, Majewski S, Hunzelmann N, Jablonka S, Orth A, Luger TA. Autocrine growth limitation of human papillomavirus type 16-harboring keratinocytes by constitutively released tumor necrosis factor alpha. J Immunol 1992; 149: 2702-2708.
56. Michiel DF, Oppenheim JJ. Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 1992; 3: 3-15.
57. Touw J, Pouweis K, Van Agthoven T, Van Gurp R, Budel L, Hoogerbrugge H, Delwel R, Goodwin R, Namen A, Lowenberg B. Interleukin-7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood 1990; 75: 2097-2101.
58. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-85.
59. Estrov Z, Kurzrock R, Talpaz M. Interruption of endogenous growth regulatory networks: a novel approach to inhibition of leukemia cell proliferation. FORUM Trends Exp Clin Med 1993; 3: 306-318.